LIVN Q1 2025 EPS $3.60–3.70 on 9–10% Cardiopulmonary Revenue Growth
- Strong OSA differentiation: The OSPREY trial showed a 65% responder rate at 12 months with rapid onset (25% response on day 1 and 50% by day 90), even among patients with severe OSA and high risk of complete concentric collapse. This robust clinical profile, along with the potential to further optimize the therapy using its unique 6-electrode architecture, positions the company to capture a significant market opportunity in the OSA segment.
- Accelerating Essenz rollout and Cardiopulmonary growth: Essenz placements are on track to increase from 40% of all HLM placements in 2024 to 60% in 2025, bolstered by new geographic approvals such as in China—its second largest market—and sustained price premium. This momentum supports a bull view for the Cardiopulmonary segment.
- Effective tariff management and improved cost control: The company’s proactive tariff mitigation strategy has limited tariff impact to less than $5 million on adjusted operating income, while continuing to strengthen its balance sheet through actions like targeted debt repayment. This enhances overall margin expansion and financial flexibility.
- Tariff Impact Concerns: Despite mitigation strategies, a $5 million tariff impact was mentioned, indicating that tariff-related cost pressures remain a risk if offset strategies are less effective than expected.
- Sustainability of International Growth: Improved OUS neuromodulation performance in Europe was highlighted, but sustaining this momentum depends on successful talent realignment and market execution, which may prove challenging in a competitive environment.
- Reliance on Revenue and Gross Margin Improvements: The emphasis on top-line and gross margin growth to cover incremental investments in areas like OSA and SNIA could expose the company if revenue growth slows or margin pressures intensify.
| Metric | YoY Change | Reason |
|---|---|---|
Total Revenue | +7.5% (from $294.9M to $316.9M) | Total Revenue increased in Q1 2025 largely due to overall growth across key segments and geographies. Higher Cardiopulmonary (+13%) and modest Neuromodulation (+3.7%) contributions, along with geographic improvements in the U.S., Europe, and Rest of World (~+5.3% to +10%), drove the increase. |
Cardiopulmonary Revenue | +13% (from $155.9M to $176.3M) | Growth was driven by strong demand for consumables and Essenz Perfusion System sales, continuing the momentum seen in previous periods where this segment outperformed. |
Neuromodulation Revenue | +3.7% (from $133.9M to $138.9M) | Neuromodulation revenue registered modest growth amid steady product mix and minor market improvements, although it lagged behind the stronger gains in Cardiopulmonary. |
Other Revenue | Declined (from $5.1M to $1.6M) | Other Revenue fell sharply, reflecting the continued wind‑down of the former ACS reportable segment, a trend that carried forward from previous periods. |
United States Revenue | +5.3% (from $160.62M to $169.2M) | The U.S. segment benefited from solid performance in both Cardiopulmonary and Neuromodulation units, continuing the upward trajectory shown in earlier results. |
Europe Revenue | ~+10% | Europe revenue increased significantly, driven by improved segment performance—particularly in Cardiopulmonary—and the stabilization of Neuromodulation, which had previously experienced mixed results. |
Rest of World Revenue | ~+10% | Growth in the Rest of World revenue reflects global market expansion and higher demand, with both Cardiopulmonary and Neuromodulation segments contributing as seen in past period trends. |
Operating Income | +200% (from $16.2M to $48.6M) | A dramatic increase in Operating Income was achieved through a combination of higher revenues, improved operational efficiencies, and better cost management relative to Q1 2024, reflecting a strong period-over-period recovery. |
Net Income | Worsened (from a loss of $41.9M to a loss of $327.3M) | Despite improved operating performance, Net Income deteriorated sharply due to a one‑time SNIA environmental liability expense of $360.4M in Q1 2025, which significantly impacted overall profitability compared to the prior period. |
Basic Income per Share | Declined (from $(0.78) to $(6.01)) | The decline in Basic Income per Share primarily reflects the steep deterioration in net income, again driven by the substantial one‑time SNIA environmental liability, marking a significant deviation from prior period results. |
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Revenue Growth (constant currency) | FY 2025 | no prior guidance | 5% to 6% on a constant currency basis. | no prior guidance |
Revenue Growth (organic basis) | FY 2025 | no prior guidance | 6% to 7% on an organic basis. | no prior guidance |
Foreign Currency Impact | FY 2025 | no prior guidance | Expected to be a headwind of 1.5% to 2% based on current exchange rates. | no prior guidance |
Adjusted Effective Tax Rate | FY 2025 | no prior guidance | Approximately 24%, representing an increase of 300 basis points versus 2024. | no prior guidance |
Adjusted Diluted EPS | FY 2025 | no prior guidance | In the range of $3.65 to $3.75. | no prior guidance |
Adjusted Diluted Weighted Average Shares Outstanding | FY 2025 | no prior guidance | Approximately 55 million for the full year. | no prior guidance |
Adjusted Free Cash Flow | FY 2025 | no prior guidance | Expected to be in the range of $135 million to $155 million. | no prior guidance |
Capital Spending | FY 2025 | no prior guidance | $90 million, a $43 million increase versus the prior year. | no prior guidance |
Cardiopulmonary Revenue Growth | FY 2025 | no prior guidance | Expected to grow 7% to 8% for the full year 2025. | no prior guidance |
Epilepsy Revenue Growth | FY 2025 | no prior guidance | Expected global epilepsy revenue growth of 4% to 5%. | no prior guidance |
| Metric | Period | Guidance | Actual | Performance |
|---|---|---|---|---|
Revenue Growth | Q1 2025 YoY | 5% to 6% on a constant currency basis; 6% to 7% on an organic basis | 7.45% YoY growth (from 294.91To 316.9) | Surpassed |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
OSA Clinical Progress and Regulatory Milestones | Q4 2024 called out that the OSPREY study met primary efficacy/safety endpoints ; Q3 2024 noted early stoppage in enrollment and upcoming PMA submission ; Q2 2024 discussed enrollment closure and follow‐up data. | Q1 2025 provided detailed 12‑month top‐line data from the OSPREY trial, with robust responder rates and rapid onset, and reinforced regulatory milestones (PMA submission with expectations for quick review). | Consistent progress with increasing data maturity and stronger regulatory positioning. |
Essenz Rollout and Cardiopulmonary Market Expansion | Q4 2024 detailed Essenz placements (40% in 2024, targeting 60% in 2025) with pricing premium and backing from improved oxygenator revenue ; Q3 2024 discussed sequential penetration and share gains along with backorder challenges ; Q2 2024 noted strong revenue growth and continuous capacity expansion efforts. | Q1 2025 emphasized further market expansion with regulatory approval in China, targets to ramp placements toward 80–100%, and clear investments in additional oxygenator capacity and new manufacturing lines. | Strong and growing theme with expanding market penetration and proactive capacity investments. |
Neuromodulation and Epilepsy Market Opportunity with Improved VNS Reimbursement | Q4 2024 reiterated milestones in de‐risking the epilepsy business and efforts on CMS submission ; Q3 2024 focused on VNS therapy reimbursement improvements as key to unlocking unmet need ; Q2 2024 highlighted underpenetration of the epilepsy market and initiatives such as remote programming. | Q1 2025 continued the strategic emphasis by highlighting large market opportunity, improved commercial execution in Europe, and progress with updated SenTiva generators alongside stable growth expectations, despite modest procedure deferrals. | A consistently positive narrative, with ongoing focus on reimbursement strategies to address an underserved market. |
Tariff Impact and Associated Cost Management Strategies | Q3 and Q2 2024 did not include commentary; Q4 2024 noted that 2025 guidance excludes tariff impacts, expecting them to be immaterial. | Q1 2025 provided a detailed analysis, estimating a modest (less than $5 million) impact on adjusted operating income and outlining a comprehensive mitigation plan (via pricing actions and supply chain reassessment). | An emerging emphasis in the current period, now quantified and actively managed, compared to earlier minimal discussion. |
Manufacturing Capacity Constraints and Supply Chain Challenges | Q4 2024 discussed capacity improvements (10% increase) and persistent oxygenator demand outpacing supply ; Q3 2024 noted industry‑wide capacity constraints and ongoing backorder situations with efforts to improve productivity ; Q2 2024 addressed strong oxygenator demand and continued investments in manufacturing capacity. | Q1 2025 reiterated strong demand for oxygenators, with reported 10% capacity increases in 2024 and plans for an additional 10% boost in 2025, plus investment in a new manufacturing line scheduled for mid‑2026. | A consistent challenge with proactive capacity expansion measures integrated into growth strategies. |
Effective Tax Rate Increases and Impact on Earnings | Q4 2024 mentioned a jump from –3% to 20% and forecast a 24% rate for 2025 ; Q3 2024 showed an increase from 10% to 23% and signaled a headwind ; Q2 2024 noted a step‑up from 10% to 21% consistent with global changes. | Q1 2025 reported an adjusted effective tax rate of 24% (up from 21% in Q1 2024), with a minor adverse impact on EPS but factored into full‑year guidance. | A steadily increasing tax rate trend that adds a headwind but is well‑incorporated into forecasts. |
Reliance on Price Increases for Revenue Growth and Margin Sustainability | Not mentioned in Q4, Q3, or Q2 2024 discussions. | Q1 2025 highlighted favorable price increases across segments as a key factor offsetting product mix and inflationary headwinds, contributing to improved organic growth outlook. | A new topic emerging in the current period, stressing pricing strategies to sustain margins. |
Rising Operating Expenses and Margin Pressure | Q2 2024 described rising SG&A and R&D investments with some margin pressure (gross margins dipping from 72% to 69%) ; Q3 2024 discussed expectations for higher expenses in Q4 and operating margin expansion despite these costs ; Q4 2024 did not elaborate further. | Q1 2025 detailed higher SG&A (up to $120 million) with decreased R&D spend, noting a slight decline in gross margin (70% vs. 71%) but improved operating income margin, while forecasting increased expenses in Q2 2025. | A recurring theme where rising expenses are managed through cost optimization and revenue growth, albeit with short-term margin pressure. |
International Expansion and Market Execution Challenges | Q2 2024 noted international epilepsy revenue growth and expansion in consumables ; Q3 2024 mentioned balanced geographic performance and market share gains but did not highlight specific challenges; Q4 2024 highlighted execution issues in OUS epilepsy and corrective measures. | Q1 2025 underscored international gains: regulatory approval in China for Essenz and 13% revenue growth in Europe/Rest of World, reflecting improved commercial execution despite some U.S. market challenges (e.g. procedure deferrals). | An ongoing focus with evolving successes in new markets (like China) and remediation of past international execution issues. |
Emerging Focus on Digital Innovation and Therapy Digitization | Q2 2024 mentioned digitization efforts in remote patient programming for VNS and continuous Essenz upgrades ; Q3 2024 featured initiatives like sensor‐based in‑line blood monitoring and next‑gen VNS connectivity ; Q4 2024 highlighted connected care strategies for VNS and software‑driven upgrades. | Q1 2025 did not explicitly address digital innovation or therapy digitization, suggesting a temporary de‑emphasis or integration into broader product updates. | A topic that was a significant focus in earlier periods but has faded or been integrated into other strategic discussions in the current period. |
Commercialization Uncertainty for High‑risk Programs (DTD) | Q2 2024 stressed dependence on CMS reimbursement and reducing DTD investment until a decision ; Q3 2024 emphasized CMS as the key gatekeeper and maintained minimal investment pending coverage ; Q4 2024 conveyed confidence via achieved clinical milestones and de‑risking progress. | Q1 2025 provided detailed discussion on optimistic revenue assumptions (midpoint of $12 million) along with ongoing commercialization challenges tied to extended CMS approval timelines and procedure deferrals. | A consistently cautious outlook, with persistent uncertainties balanced by strategic revenue adjustments and incremental progress. |
SNIA Investments | Q2 2024 mentioned SNIA in the context of the ECJ ruling on demerger liabilities ; Q3 2024 did not reference SNIA; Q4 2024 updated on pending hearing and its non‑inclusion in 2025 guidance. | Q1 2025 treated SNIA as a resolved issue, having recorded the liability, executed partial debt repayment, and essentially faded it as a management focus to allow capital re‑allocation. | A topic that has gradually faded from strategic conversation as resolution and associated capital actions have clarified its impact. |
-
EPS Guidance
Q: What's driving EPS uplift?
A: Management noted that resolving the SNIA liability and achieving stronger revenue and margin performance have boosted adjusted diluted EPS guidance to $3.60–$3.70, with FX impacts largely hedged despite minor tariff headwinds. -
Cardiopulm Outlook
Q: How is CP growth trending?
A: With robust HLM placement performance and new regulatory approval in China, management now expects Cardiopulmonary revenue to grow 9%–10%, reflecting strong market demand and capacity expansion. -
Leverage Impact
Q: What’s the post-SNIA leverage status?
A: Following a $200 million debt repayment amid SNIA adjustments, management assures that the company’s leverage remains very healthy, supporting flexible capital allocation. -
Revenue/Margin Improvements
Q: Are revenue and margin gains sufficient?
A: A $0.21 improvement in margins, driven by higher gross margins and revenue increases, has effectively offset incremental investments, reinforcing the solid top-line performance. -
Tariff Management
Q: How are tariffs affecting margins?
A: Tariff impacts are expected to be minimal—less than $5 million on adjusted operating income—with planned pricing actions effectively offsetting these headwinds. -
OSA Data
Q: What does OSA data signal?
A: The OSPREY trial demonstrated a 65% responder rate at 12 months with rapid therapeutic onset, underscoring a strong competitive position for the new hypoglossal nerve stimulation therapy. -
HLM Outlook
Q: How is HLM performing?
A: Essenz placements have risen from 40% to 60% penetration, and oxygenator demand remains high, supported by ongoing capacity expansion to meet market needs. -
U.S. Epilepsy Visibility
Q: What’s the U.S. Epilepsy outlook?
A: Confidence remains strong in the U.S. Epilepsy market, with sustained mid-single-digit growth driven by broad patient access under the company’s market leadership. -
Depression Revenue
Q: What's the DTD revenue guidance?
A: Guidance for the difficult-to-treat depression segment has been modestly increased to a midpoint of $12 million, reflecting renewed focus on program optimization. -
Sleep Apnea Pricing
Q: What about OSA procedure and pricing?
A: An efficient procedure time averaging 72 minutes highlights the streamlined implant process, while the pricing strategy is still being defined for optimal market positioning. -
OUS Neuromodulation
Q: How's growth outside the U.S.?
A: Enhanced commercial execution in Europe and other international markets is sustaining healthy growth in neuromodulation outside the United States. -
Guidance Sequencing
Q: How are quarterly results structured?
A: The sequential guidance shows a ramp in operating expenses with net interest expense included from Q2, aligning with an expected Q2 EPS of about $0.97.